| Date |
Title (click to view the full text) |
| November 20, 2009 | European CHMP Formally Adopts Negative Opinion on Oncophage® |
| October 26, 2009 | Data Presented On Oncophage Cancer Vaccine In Recurrent Glioma At SNO 2009 |
| October 21, 2009 | Antigenics Announces a Negative Vote From the CHMP on Oncophage® Marketing Application in Europe |
| August 12, 2009 | Patients Begin Enrolling into Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage® Cancer Vaccine in Newly Diagnosed Glioma |
| June 25, 2009 | Antigenics Announces Expansion of Investigator-Sponsored Study for Glioma |
| June 1, 2009 | Antigenics Presents Positive Oncophage® Interim Survival Data at ASCO |
| April 29, 2009 | FDA Grants Orphan Drug Designation to Oncophage for the Treatment of Glioma |
| March 12, 2009 | Antigenics’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Brain Cancer |
| November 24, 2008 | Final Data From Phase 1 Investigator-Sponsored Trial of Oncophage® Cancer Vaccine in Glioma Presented at the Society for Neuro-Oncology’s Annual Meeting |
| November 3, 2008 | Antigenics to Present at the Rodman and Renshaw 10th Annual Healthcare Conference |
| October 22, 2008 | Antigenics Submits Oncophage® Application for European Approval |
| September 29, 2008 | FDA Grants Permission For Export of Antigenics’ Oncophage to Russia |
| April 8, 2008 | Oncophage® Approved in Russia for the Treatment of Intermediate-Risk Kidney Cancer |
| February 20, 2008 | Antigenics Announces Publication of Phase 3 Melanoma Study Results in Journal of Clinical Oncology |
| October 25, 2007 | Data From Investigator-Sponsored Trial of Oncophage® Cancer Vaccine in Glioma Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics |
| October 10, 2007 | First Patient Registered in Investigator-Sponsored Phase 2 Trial of Antigenics’ Oncophage Cancer Vaccine in Glioma |
| August 2, 2007 | Antigenics Provides Update on Filing for Approval of Oncophage® in Russia for the Treatment of Intermediate-Risk Kidney Cancer |
| May 21, 2007 | Oncophage® Cancer Vaccine Significantly Prolongs Recurrence-Free Survival by 45 Percent in Patients With Intermediate-Risk Kidney Cancer |
| April 16, 2007 | Data From Investigator-Sponsored Trial of Oncophage® Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting |
| November 16, 2006 | Data From Investigator-Sponsored Trial of Oncophage® Cancer Vaccine in Glioma Presented at Immunotherapy Task Force Meeting at the Society of Neuro-Oncology’s Annual Meeting |
| June 7, 2006 | Antigenics Announces Results From In-Depth Analysis of Phase 3 Data of Oncophage in Kidney Cancer and Provides Regulatory Update |
| June 5, 2006 | Antigenics Presents Phase 3 Data From Trial of Oncophage in Metastatic Melanoma at ASCO Meeting |
| March 24, 2006 | Antigenics Reports Phase 3 Results for Oncophage in Kidney Cancer |
| November 21, 2005 | First Patient Enrolled in Investigator-Sponsored Phase 1/2 Trial of Antigenics’ Oncophage Cancer Vaccine in Glioma |
| October 10, 2005 | Antigenics Announces Preliminary Survival Data From Its Randomized Phase 3 Metastatic Melanoma Trial |
| June 7, 2005 | Antigenics’ Oncophage Cancer Vaccine Receives European Orphan Drug Designation for Renal Cell Carcinoma |
| June 7, 2004 | Phase 3 Demographic Data on Antigenics’ Oncophage Cancer Vaccine in Kidney Cancer Published at ASCO Meeting |
